Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AM Rx vs Shapely

AM Rx
Graded #491

Lower grade

vs+15.800000000000004
Shapely
Graded #225

Higher grade

The verdict

Shapely takes it — 65.4/100 to 49.6/100.

Shapely grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Shapely is a GLP-1 telehealth platform founded by Dr.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAM Rx +5
50
45
Dose & formulationAM Rx +12
65
53
Clinical oversightShapely +53
41
94
Labs & monitoringShapely +24
49
73
FulfillmentShapely +20
58
78
Contract termsShapely +35
20
55
AM Rx · left barShapely · right bar

The numbers

MetricAM RxShapely
WeighScore49.6/10065.4/100
GradeCC
Scorecard rank#491#225
Semaglutide$151/mo (quarterly plan, plus a separate fee, compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not published4 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
AM Rx

Graded #491 · C

Strengths

  • Insurance coordination for brand-name GLP-1s — as low as $25/mo
  • All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
  • HSA and FSA accepted
  • Video visits available with providers averaging 10+ years' experience
  • Compounded semaglutide from $151/mo on the quarterly plan

Where it loses points

  • Active FTC/DOJ lawsuit over deceptive billing and subscription practices
  • Novo Nordisk false-advertising lawsuit (Aug 2025)
  • Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
  • Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Shapely

Graded #225 · C

Strengths

  • Founded by Dr. Justin Zaghi, MD/MBA — Harvard-trained, board-certified in internal medicine and obesity medicine, with Medical Director Ana Lisa
  • Brand-name GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo) covered by major PPO and Medicare at copay
  • Compounded semaglutide from $99/month with free 2-day shipping, syringes, and supplies included via 503A/503B pharmacy
  • 1:1 registered dietitian (RDN) and monthly video provider visits included in every plan; unlimited chat and app support
  • Cellular smart scale provided to qualifying patients for ongoing weight tracking throughout the program

Where it loses points

  • Currently available only in California, Florida, New York, and Texas — 46 states unserved despite announced expansion
  • Telehealth subscription ($99/mo self-pay, $49 first-month promo) is charged separately from compounded medication cost
  • Labs not included — $75 flat rate for uninsured patients; baseline bloodwork may be required before prescribing
  • No LegitScript certification found on any public page
  • Compounding pharmacy partner not named publicly; 503A/503B status claimed but specific pharmacy undisclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard